February 26, 2014

Margaret A. Hamburg, M.D.,
Commissioner
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

RE: New Drug Application NDA 202880, Zohydro ER

Dear Dr. Hamburg,

We are writing to echo concerns raised in letters written by Members of the United States Congress and by State Attorneys General regarding the Food and Drug Administration’s (FDA) approval of Zohydro, a high-dose, single-entity hydrocodone formulation. We join them in asking you to adopt the recommendation of the FDA-appointed scientific advisory panel, which voted 11-2 against approval of Zohydro.

On behalf of consumer safety organizations, health care agencies, addiction treatment providers, community-based drug and alcohol prevention programs, professional organizations, and other groups on the front-line of our nation’s opioid addiction epidemic, we ask you to put the public’s health ahead of industry interests. In the midst of a severe drug addiction epidemic fueled by overprescribing of opioids, the very last thing the country needs is a new, dangerous, high-dose opioid.

If your decision to approve Zohydro was based on adherence to existing FDA policies, then surely those policies require urgent revision. FDA must take into account recent history. After the release of similar high-dose opioid analgesics, thousands of lives were lost from overdose and hundreds of thousands of medical and non-medical users became addicted. We implore you to take these painful lessons into account.

Over the past 15 years, prescriptions for opioids have skyrocketed. The United States, with about 5% of the world’s population, is now consuming more than 84% of the world’s entire oxycodone supply and more than 99% of the hydrocodone supply. According to the United States Centers for Disease Control (CDC), the sharp increase in opioid prescribing has led to parallel increases in opioid addiction and overdose deaths. Since 1999, overdose deaths have skyrocketed, especially among middle-aged individuals prescribed opioids for chronic pain. Opioid analgesic overdose deaths have increased by 415% in women and 265% in men.

Zohydro’s maker has claimed that it is safer than existing hydrocodone products because it does not contain acetaminophen. Zohydro is not safer. The highest available dosage of Zohydro will contain 5 to 10 times more hydrocodone than Vicodin or Lortab. Someone unaccustomed to taking opioids could suffer a fatal overdose from just two capsules. A single capsule could be fatal if swallowed by a child. For patients unable to tolerate acetaminophen, many opioid formulations made without acetaminophen are already available. There is no need for another high-dose, single-entity opioid.

Too many people have already become addicted to similar opioid medications and too many lives have been lost. We urge you to exercise your authority and responsibility to protect the public’s health by keeping Zohydro off the market.

Sincerely,

---

1 United States hydrocodone and oxycodone consumption statistics as reported by the International Narcotics Control Board in 2012.

David Healy, MD, FRCP
Co-Founder
RxISK.org/Data Based Medicine
Toronto, Canada

Peter W. Jackson
President
Advocates for the Reform of Prescription Opioids, Inc. (ARPO)
Chicago, IL

Teri Kroll
Coordinator
People United to Stop Heroin on Long Island (PUSH-LI)
Mineola, NY

Rebecca McGoldrick
Executive Director
Protect Families First
Providence, RI

Katherine M. McHugh
Chair
Freedom from Addiction Network (FAN)
Hyannis, MA

Howard Meitiner
President and CEO
Phoenix House
New York, NY

Joanne Peterson
Founder and Executive Director
Learn2Cope
Boston, MA

Raghu Ram, MD
Vice President and Chief Medical Officer
HealthNow New York Inc., d/b/a
BlueCross BlueShield of Western New York (Buffalo) and
BlueShield of Northeastern New York (Albany)

Avi Israel
Avi Israel
President
Save the Michaels of the World
Buffalo, NY

Andrew Kolodny, MD
President
Physicians for Responsible Opioid Prescribing (PROP)
New York, NY

Danesh Mazloomdoost, MD
Founder
Pain Management Medicine
Lexington, KY

Janis McGrory
Founder
Lower Cape Community Anti-Drug Network
Cape Cod, MA

Michele McTiernan-Gleason
Director of Recovery Wellness
Connect the Pieces to Prevent Prescription Drug Abuse
Boise, ID

Karen H. Perry
Executive Director
NOPE Task Force
West Palm Beach, FL

Mel Pohl, MD
Medical Director
Las Vegas Recovery Center
Las Vegas, NV

April J. Rovero
President
National Coalition Against Prescription Drug Abuse (NCAPDA)
San Ramon, CA
Jeffrey L. Reynolds, Ph.D., CEAP, SAP  
Executive Director  
Long Island Council on Alcoholism & Drug Dependence (LICADD)  
Mineola, NY

Sherrie Rubin  
Director  
The Hope2gether Foundation  
San Diego, CA

Judy Rummiller  
President  
Steve Rummiller Hope Foundation  
Minneapolis, MN

Susan Salomone  
Founder  
Drug Crisis in our Backyard  
Mahopac, NY

Marvin D. Seppala, MD  
Chief Medical Officer  
Hazelden Foundation  
Center City, MN

Dan Smoot  
President and CEO  
Operation UNITE  
London, KY

Raymond V. Tamasi  
President and CEO  
Gosnold on Cape Cod  
Falmouth, MA

Ken Thompson, MD  
Trusted Servant  
Like Minded Docs  
Strasburg, PA

Dirk Wales  
Director  
Get Unhooked  
Santa Fe, NM

Kim Witczak  
Founder  
WoodyMatters.com  
Minneapolis, MN